|
|
Discovering causal genes, brain regions and other risk factors for Alzheimera disease |
| 1 R01 AG065636-01 |
PAN, WEI |
NIA |
2020 |
|
|
Guiding next steps for SPRINT-MIND implementation: Identifying high-benefit subgroups and comparative effects of ARB- vs. ACEI-based regimens |
| 1 R01 AG065805-01A1 |
BRESS, ADAM P |
NIA |
2020 |
|
|
R01 Upstream Approaches to Improve Late Life Care for People Living with Dementia |
| 1 R01 AG066139-01A1 |
JARRÍN MONTANER, OLGA F |
NIA |
2020 |
|
|
Mapping Molecular and Phenotypic Interactions in Alzheimers Disease |
| 1 R01 AG066490-01 |
MONTGOMERY, STEPHEN BLAIR |
NIA |
2020 |
|
|
Connecting long-lived protein isomerization to lysosomal failure in Alzheimers disease |
| 1 R01 AG066626-01 |
JULIAN, RYAN ROY |
NIA |
2020 |
|
|
Endophenotype Network-based Approaches to Prediction and Population-based Validation of in Silico Drug Repurposing for Alzheimers Disease |
| 1 R01 AG066707-01 |
CHENG, FEIXIONG |
NIA |
2020 |
|
|
Complexity of FMRI in Alzheimers Disease |
| 1 R01 AG066711-01 |
JANN, KAY |
NIA |
2020 |
|
|
Identifying Alzheimer’s Disease Causal Variants and Target Genes Using iPSC-derived Microglia |
| 1 R01 AG066871-01 |
PHANSTIEL, DOUGLAS |
NIA |
2020 |
|
|
Reversing Loss of Metabolic Homeostasis to Ameliorate Alzheimers Disease Pathogenicity |
| 1 R01 AG067106-01 |
MAIR, WILLIAM B |
NIA |
2020 |
|
|
Microglial TREM2 Interactome in Alzheimers Disease |
| 1 R01 AG067606-01 |
KIM, TAE-WAN |
NIA |
2020 |
